 VANCOUVER, British Columbia, July 27, 2021 GLOBE NEWSWIRE -- BetterLife Pharma Inc. BetterLife or the Company CSE: BETR OTCQB: BETRF FRA: NPAU today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. Altum, and Pontificia Universidad Católica de Chile have obtained approval from the Instituto de Salud Publica de Chile to conduct their planned randomized placebo-controlled trial IN2COVID in COVID-19 patients. The trial, set to start in early August, tests BetterLifes proprietary inhaled interferon alpha-2b IFN-a2b product, AP-003. 